Weatherbie Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$2.46M Buy
85,300
+79,200
+1,298% +$2.1M 0.31% 47
2016
Q3
$194K Hold
6,100
0.02% 64
2016
Q2
$198K Sell
6,100
-2,400
-28% -$80.3K 0.03% 65
2016
Q1
$238K Buy
8,500
+4,400
+107% +$95.9K 0.03% 65
2015
Q4
$146K Buy
+4,100
New +$144K 0.02% 70

Other funds holding ACAD

Weatherbie Capital's ACAD Position: Q4 2016 in Review

Weatherbie Capital increased its Acadia Pharmaceuticals (ACAD) stake by 244% in Q4 2016, buying an estimated $10.8M and bringing the position to 576,784 shares worth $16.6M. The position accounts for 2.09% of the portfolio, ranked #19.

Weatherbie Capital first reported a position in ACAD in Q3 2014 and has held it in 10 quarters since. The position peaked at $22.8M in Q1 2015. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Weatherbie Capital held 576,784 shares of Acadia Pharmaceuticals worth $16.6M as of Q4 2016.
  • Weatherbie Capital bought 409,034 Acadia Pharmaceuticals shares in Q4 2016, an estimated $10.8M.
  • Acadia Pharmaceuticals made up 2.09% of Weatherbie Capital's portfolio in Q4 2016, its #19 holding.
  • Weatherbie Capital first reported a position in Acadia Pharmaceuticals in Q3 2014 and has held it in 10 quarters since.
  • Weatherbie Capital's Acadia Pharmaceuticals position peaked at $22.8M in Q1 2015.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Weatherbie Capital's 13F filing for Q4 2016, filed 14 Feb 2017.